This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Eze N , Lee JW , Yang DH , Zhu F , Neumeister V , Sandoval-Schaefer T , Mehra R , Ridge JA , Forastiere A , Chung CH , Burtness B
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma
Oral Oncol. 2019 Apr;91 :69-78
PMID: 30926065 PMCID: PMC6855599 URL: https://www.ncbi.nlm.nih.gov/pubmed/30926065
AbstractINTRODUCTION: Cetuximab, a monoclonal antibody to the epidermal growth factor receptor (EGFR), extends survival in combination with standard therapy in head and neck squamous cell carcinoma (HNSCC). However, as effects are modest, and patients experience side effects, a biomarker to predict resistance and personalize therapy is needed. Activation of signaling pathways downstream from receptor tyrosine kinases predicts resistance to such therapies in other cancers. The most common abnormalities downstream from EGFR in HNSCC are in the PI3K pathway, activated via loss of expression of the regulator PTEN, or via PI3K mutation. We studied whether PTEN and/or PI3K abnormalities predict resistance to cetuximab. METHODS: Tumor PTEN and PIK3CA/PI3K p110alpha were analyzed in samples from subjects treated on two trials of cetuximab-based therapy for patients with metastatic or recurrent HNSCC: E5397, a randomized trial of cisplatin plus placebo versus cisplatin plus cetuximab; and NCI-8070, a randomized trial of cetuximab plus sorafenib versus cetuximab. In situ quantification of PTEN and PI3K p110 alpha was performed using the AQUA method of quantitative immunofluorescence. PI3KCA hot spot mutations were determined with BEAMing. RESULTS: For E5397, in multivariable analysis, PTEN expressing/PIK3CA WT patients tended to improve PFS with cetuximab compared to placebo (N=48; HR=0.54, Wald p=0.0502). High PTEN expression was significantly associated with superior PFS among patients treated on NCI-8070 (N=37; HR=0.35, p=0.008). CONCLUSION: Loss of PTEN expression may be associated with lack of benefit from cetuximab. This analysis is limited by small sample size, and PTEN as a potential predictive biomarker merits validation in larger sample sets.
Notes1879-0593 Eze, Nnamdi Lee, Ju-Whei Yang, Dong-Hua Zhu, Fang Neumeister, Veronique Sandoval-Schaefer, Teresa Mehra, Ranee Ridge, John A Forastiere, Arlene Chung, Christine H Burtness, Barbara Journal Article England Oral Oncol. 2019 Apr;91:69-78. doi: 10.1016/j.oraloncology.2019.02.026. Epub 2019 Mar 4.